Real-World Case Series of Omidubicel-Onlv for Allogeneic Transplantation in Patients with Hematologic Malignancies Using a Reduced Toxicity Myeloablative Conditioning Regimen | Synapse
March 3, 2026
Real-World Case Series of Omidubicel-Onlv for Allogeneic Transplantation in Patients with Hematologic Malignancies Using a Reduced Toxicity Myeloablative Conditioning Regimen
Puntos clave
Omidubicel shows potential for improving outcomes after allogeneic transplantation in patients with hematologic malignancies.
The study highlights the use of a reduced toxicity myeloablative conditioning regimen that may enhance recovery.
Analysis includes data from multiple cases, indicating promising efficacy and tolerability of the intervention.
These findings support the need for further studies on omidubicel's role in transplantation protocols.